News Archive
Successful exit for PVP: Cytiva buys our portfolio Company CEVEC
CEVEC is now part of Cytiva
Read more … Successful exit for PVP: Cytiva buys our portfolio Company CEVEC
Miracor Medical - New PiCSO Publication
Microvascular dysfunction after successful primary PCI is frequent and contributes to poor outcomes in STEMI.
RZNOMICS advance its lead compound, a gene therapy produced using CEVEC's CAP® Ad Technology, into clinical development
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
Miracor Medical starts 2nd randomized study, targeting expanded indications
300 patients have been treated with PiCSO®
Read more … Miracor Medical starts 2nd randomized study, targeting expanded indications
CryoTherapeutics receives additional funding and launches a new clinical study
CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.
Read more … CryoTherapeutics receives additional funding and launches a new clinical study
Emperra's EYSYTA in the "Handelsblatt" newspaper
Emperra's digital diabetes management solution ESYSTA among the five trends for the healthcare system of the future in the "Handelsblatt" newspaper:
Click here for the article!
Read more … Emperra's EYSYTA in the "Handelsblatt" newspaper
Implandata Ophthalmic Products GmbH gewinnt ersten Preis bei der Medizintechnik-Messe Medica
Deutsches Tech-Start-up gewinnt ersten Preis bei der Medica
Auf der Medizintechnik-Messe Medica in Düsseldorf wurden zwei junge Tech-Firmen mit Preisen gewürdigt. Die Start-ups hoffen durch die Auszeichnung auf mehr Sichtbarkeit.
CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an agreement with UCB S.A. (UCB; Euronext: UCB) on the evaluation and use of CEVEC’s proprietary ELEVECTA® Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.
CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies
CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, today announced the successful closing of an internal growth financing round.
Emperra's digital diabetes management solution ESYSTA now on prescription
Congratulations to our portfolio company Emperra GmbH E-Health Technologies for the listing of their ESYSTA App as the first Diabetes DiGA and becoming the first broadly reimbursed digital diabetes solution in Germany. This is a major achievement and will help many diabetic patients in their daily life.
Read more … Emperra's digital diabetes management solution ESYSTA now on prescription